AesPLLA 365mg

Inject only into the deep dermis. Reconstitute the vial for a minimum of 3 hours (0.9% NaCl) before treatment — too short reconstitution time, too superficial placement or no post-treatment massage increases the risk of nodules. After treatment: massage the injection area 3 times daily for 3–5 days. The periocular area is excluded.

What is AesPLLA 365 mg?

AesPLLA 365 mg is a Korean tissue stimulator based on poly-L-lactic acid (PLLA), intended for professional use in aesthetic medicine. It is designed for mature skin: supporting volume restoration, skin density and the appearance of fine expression lines and deeper folds. The CE1434 certificate confirms that the product meets European safety and quality requirements for a medical device.

What is poly-L-lactic acid (PLLA)?

PLLA (poly-L-lactic acid) is a biocompatible, biodegradable synthetic polymer. It naturally degrades in the body to water and carbon dioxide. PLLA, as a biodegradable polymer particle, is FDA-cleared for medical uses (e.g. surgical sutures and resorbable implants). This refers to the substance and is not equivalent to FDA approval of the AesPLLA product itself.

In aesthetic medicine PLLA acts as a long-term biostimulator: after placement in the deep dermis, the polymer particles elicit a controlled tissue response that over time stimulates fibroblasts to produce collagen. The effect is not immediate — it develops gradually and may last longer than with conventional hyaluronic acid fillers.

How AesPLLA works – mechanism of action

After injection into the deep dermis, PLLA microparticles act in three stages:

• Stage 1 – inflammatory response (1–2 weeks): PLLA particles trigger a controlled, physiological inflammatory reaction; fibroblasts are recruited to the injection site.
• Stage 2 – stimulation of collagenogenesis (4–12 weeks): fibroblasts produce collagen de novo, densifying the dermal structure. First visible effects appear about 4 weeks after treatment.
• Stage 3 – biodegradation and consolidation (up to 3 years): PLLA particles gradually degrade to lactic acid, which is metabolised naturally. Newly formed collagen remains in the tissue; effects may last 2–3 years.

How does PLLA differ from an HA filler?

HA filler acts immediately and mechanically: it occupies tissue space and increases volume, but does not stimulate the skin’s own collagen production. The effect lasts 6–18 months.

AesPLLA (PLLA) acts biologically and gradually: it does not fill mechanically, but stimulates the skin to rebuild its own collagen. The effect builds over several weeks and lasts up to 3 years. This is a regenerative procedure rather than a typical filling treatment.

PLLA and HA fillers can be combined in a comprehensive plan, as they act complementarily at different tissue levels.

Composition and the role of each ingredient

One AesPLLA 365 mg vial contains 365 mg of powder, including:

• Poly-L-lactic acid (PLLA) – 150 mg — the active substance responsible for collagen biostimulation.
• Sodium carboxymethylcellulose (CMC) – 90 mg — an excipient that stabilises the preparation, improves rheology and helps distribute PLLA evenly in the tissue after injection.
• Mannitol – 125 mg — a sugar alcohol that prevents PLLA particles from aggregating during lyophilisation and storage.

INCI: Poly-L-lactic acid, Sodium Carboxymethylcellulose, Mannitol.

Indications and treatment areas

AesPLLA is intended for use in the following indications and areas, among others:

• skin laxity and loss of density in people over 30,
• deep folds, including nasolabial folds and marionette lines,
• fine and moderate expression wrinkles,
• soft-tissue volume loss of the face, neck and décolleté,
• skin of the hands — restoring volume and density,
• support for the appearance of scarred skin, including post-acne scars,
• body volumising procedures (modelling of the buttocks and breasts).

Excluded area: the periocular region.

Preparation and injection technique

Reconstitution:

• dissolve the vial contents in 5 ml of physiological saline (0.9% NaCl),
• leave for a minimum of 3 hours for full dispersion of PLLA particles — essential for a homogeneous solution,
• optional: add 1 ml of 2% lidocaine to reduce injection discomfort,
• use the prepared solution within 72 hours of opening and store it in a refrigerator.

Injection technique:

• injection layer: deep dermis,
• recommended technique: linear (retrograde) or cross-hatching,
• recommended needle/cannula size: 26G,
• after treatment: massage the injection area 3 times daily for 3–5 days to distribute PLLA particles evenly and reduce the risk of nodules.

Effects and duration

Expected effects — not a guarantee of results in every patient:

• After 4 weeks — first visible effects: improved skin tightness and hydration, early densification,
• After 2–3 months — fuller collagenogenesis: skin densification, smoothing of wrinkles, restoration of contour,
• Up to 3 years — duration depending on individual skin characteristics, age, lifestyle and the number of sessions.

The usual recommendation is 2–3 sessions at 4–6-week intervals; the number of sessions depends on skin condition and the practitioner’s assessment.

Contraindications

• pregnancy and breastfeeding,
• active inflammation or infection at the injection site,
• autoimmune diseases,
• tendency to hypertrophic scars or keloids,
• hypersensitivity to any ingredient of the preparation,
• coagulation disorders or anticoagulant therapy (medical consultation required),
• the periocular area — the product is not indicated in this zone.

Additional contraindications include: active herpes, active neoplastic disease, and recently performed aesthetic procedures in the same area.

Product data

• Pack contents: 1 × 5 ml vial of lyophilised powder 365 mg (PLLA 150 mg + CMC 90 mg + mannitol 125 mg)
• EAN: 08800125100058
• Certificate: CE1434 — medical device
• Manufacturer: PRP Science Co., Ltd., #403, Kyeong-Won Building, Samsung-ro 149-gil 32, Gangnam-gu, 149-gil 32, Seoul, South Korea

FAQ

How does AesPLLA differ from Sculptra?

Both preparations are based on PLLA and act through a similar collagen-biostimulation mechanism. AesPLLA is described as a Korean alternative with a PLLA + CMC + mannitol composition and CE1434 certification. A detailed comparison of concentrations and protocols should always be based on both manufacturers’ leaflets.

When are the first results visible?

First visible effects appear about 4 weeks after treatment. A fuller collagenogenesis effect develops over 2–3 months and may last up to 3 years, depending on individual skin characteristics.

How many sessions are needed?

The usual recommendation is 2–3 sessions at 4–6-week intervals. The number of sessions depends on individual skin condition and the practitioner’s assessment.

Why must the preparation stand for 3 hours before treatment?

PLLA particles need to fully disperse in saline. Too short a reconstitution time leads to a non-homogeneous solution, which may promote nodules in the tissue and reduce treatment quality.

Can AesPLLA be combined with an HA filler or botulinum toxin?

PLLA and HA fillers act at different tissue levels and may complement each other. AesPLLA can be combined with other aesthetic procedures if appropriate time intervals are observed, according to the practitioner’s assessment.

Why must the skin be massaged after treatment?

Massage 3 times daily for 3–5 days after treatment is intended to distribute PLLA particles evenly in the tissue and reduce the risk of nodules.

AesPLLA is intended for use only by physicians and cosmetologists trained in aesthetic medicine who are authorised to perform injections. Place only in the deep dermis; the periocular area is excluded. Mandatory reconstitution in 0.9% NaCl for a minimum of 3 hours, 26G needle/cannula, post-treatment massage 3 times daily for 3–5 days. Dissolve the vial contents in 5 ml of 0.9% NaCl and leave for a minimum of 3 hours (optionally + 1 ml of 2% lidocaine). Read the manufacturer’s instructions for use before application. By purchasing, you confirm that you hold the required professional qualifications.

• What is AesPLLA 365 mg?
• What is poly-L-lactic acid (PLLA)?
• How AesPLLA works – mechanism of action
• Composition and the role of each ingredient
• Indications and treatment areas
• Preparation and injection technique
• Product data
• FAQ